Related Experiment Video
Updated: Sep 19, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Long-term comorbidities and mortality associations with treatment in generalized pustular psoriasis: a
Teng-Li Lin1,2, Yi-Hsuan Fan3, Kuo-Sheng Fan4
1Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
Background:
Generalized pustular psoriasis (GPP) is a rare, severe inflammatory disease with limited evidence on long-term prognosis and treatment-mortality associations.
Objective:
To compare mortality and major comorbidities in GPP, psoriasis vulgaris (PV), and non-psoriatic individuals, and treatment-mortality associations in GPP.
Methods:
Adults with GPP, psoriasis vulgaris (PV) without pustular psoriasis, and non-psoriatic controls were identified. GPP patients were 1:1 propensity score-matched to PV and non-psoriatic controls by age, sex, and race. Among GPP patients, those receiving biologics, conventional anti-psoriatic drugs, or small-molecule inhibitors were separately matched to patients treated with systemic corticosteroids alone. Primary outcome was all-cause mortality; secondary outcomes included major mortality-related comorbidities based on the ten leading causes of death per US CDC. Kaplan-Meier and Cox models estimated cumulative incidence and hazard ratios.
Results:
After matching, 6,959 GPP-PV and 28,459 GPP-non-psoriatic pairs were analyzed. Over 5 years, GPP patients had higher 5-year mortality than PV (HR, 1.83; 95% CI, 1.28-2.59) and non-psoriatic controls (HR, 2.42; 95% CI, 1.99-2.94). Major comorbidity risks were higher in GPP than in PV, notably ischemic heart disease (HR, 1.34; 95% CI, 1.01-1.78), cerebrovascular disease (HR, 1.62; 95% CI, 1.06-2.47), and neurodegenerative disease (HR, 2.94; 95% CI, 1.47-5.89), and were elevated across all evaluated comorbidities compared with non-psoriatic controls. Mortality risks were particularly pronounced in patients >60 years and males. Among GPP patients, biologic therapy was associated with lower mortality than systemic corticosteroids alone (HR, 0.71; 95% CI, 0.52-0.96), whereas conventional anti-psoriatic drugs and small-molecule inhibitors were not.
Conclusion:
GPP is associated with higher mortality and comorbidity risk than PV and non-psoriatic individuals. Biologic therapy was associated with lower mortality.
